Vaccine Therapy in Treating Patients With Advanced Cancer
Unspecified Adult Solid Tumor, Protocol Specific
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
The U.S. Food and Drug Administration (FDA) has approved both gene- and immune-targeted drugs for tissue-agnostic, genomic biomarker–based indications in patients with lethal solid tumors and blood cancers. High response rates were the basis for these approvals.[1]
Sources: 1
Precision medicine has rapidly changed the oncology field. Next-generation sequencing can identify patients with specific gene alterations or immune markers for which there are targeted therapies. Biomarker-based treatments are increasingly emerging, and the FDA has approved the following tissue-agnostic therapies:[1,2]
Pembrolizumab.
Dostarlimab.
Entrectinib.
Larotrectinib.
Repotrectinib.
Dabrafenib in combination with trametinib.
Selpercatinib.
Pemigatinib.
Trastuzumab deruxtecan.
Precision medicine is constantly evolving, and improved diagnostic tools allow for more comprehensive genomic definition of the tumor. Tissue-agnostic targeted therapies are a promising treatment strategy tailored to the specific tumor genomic profile, leading to improved patient survival outcomes.
The list of drugs approved for tumors with genomic alterations will likely expand as understanding of the science driving these cancers continues to advance. As oncology drug development continues to move rapidly, the location where the cancer originated will become less critical.
Companion tests can determine the presence of specific genomic alterations or immune markers. These tests may have been approved by the FDA as part of the agnostic drug approval. Most insurance companies have not required these specific tests before covering the prescribed medications.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. Pembrolizumab is indicated for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H)/microsatellite unstable or mismatch repair–deficient (dMMR) solid tumors whose disease progressed after prior treatment and who have no satisfactory alternative treatment options. The MSI-H phenotype is associated with germline defects in the MLH1, MSH2, MSH6, and PMS2 genes and is the primary phenotype observed in tumors from patients with hereditary nonpolyposis colorectal cancer or Lynch syndrome. Patients can also have the MSI-H phenotype because one of these genes was silenced via DNA methylation. Molecular genetic tests look for microsatellite instability in the tumor tissue, and immunohistochemistry tests for the loss of mismatch repair proteins. For more information, see the Immunotherapy section in Colon Cancer Treatment.
Sources: Immunotherapy
Evidence. The U.S. Food and Drug Administration (FDA) approval was based on data from the following five uncontrolled, multicohort, multicenter, single-arm clinical trials that included 149 patients with MSI-H or dMMR cancers:[1][Level of evidence C3]
Sources: 1 · Level of evidence C3
KEYNOTE-016 (NCT01876511) (median follow-up, 5.3 months).[2]
Sources: KEYNOTE-016 · 2
KEYNOTE-164 (NCT02460198) (median follow-up, 31.3 months).[3]
Sources: KEYNOTE-164 · 3
KEYNOTE-012 (NCT01848834) (median follow-up, 9 months).[4]
Sources: KEYNOTE-012 · 4
KEYNOTE-028 (NCT02054806) (median follow-up, 9.8 months).[5]
Sources: KEYNOTE-028 · 5
KEYNOTE-158 (NCT02628067) (median follow-up, 13.4 months).[6]
Sources: KEYNOTE-158 · 6
These trials included 90 patients with colorectal cancer and 59 patients with other cancers who were diagnosed with one of 14 other cancer types. Patients received either 200 mg of pembrolizumab every 3 weeks or 10 mg/kg of pembrolizumab every 2 weeks.
Efficacy. The major efficacy outcome measures were objective response rate, assessed by blinded independent central radiologist review according to RECIST 1.1, and response duration. The pooled objective response rate was 39.6%. A total of 11 patients (7.4%) had a complete response and 48 patients (32.2%) had a partial response. The objective response rate was 36% in patients with colorectal cancer, and 46% in patients with other cancers (95% confidence interval [CI], 33%–59%).[7,8] Responses lasted 6 months or longer for 78% of patients who responded to pembrolizumab.[1]
Identification of biomarker. For most patients (135 of 149), tumor status was prospectively determined using local laboratory-developed, investigational polymerase chain reaction (PCR) (for MSI-H) or immunohistochemistry (for dMMR).[9] For 14 of the 149 patients, MSI-H status was determined in a retrospective assessment of tumor samples from 415 patients using a central laboratory-developed PCR test.
Sources: 9
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. Dostarlimab is indicated for adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, whose disease progressed during or after prior treatment and who have no satisfactory alternative treatment options. This indication is not approved in the pediatric population.
Evidence. GARNET (NCT02715284) was a nonrandomized, multicenter, open-label, multicohort trial that evaluated the efficacy of dostarlimab.[10] The expansion cohorts were as follows:[11-14][Level of evidence C3]
Sources: GARNET · 10 · 11 · 14 · Level of evidence C3
dMMR/MSI-H endometrial cancers.
Mismatch repair–proficient or microsatellite stable endometrial cancers.
Non-small cell lung cancers.
Non-endometrial dMMR/MSI-H and POLE-mutated cancers.
High-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without BRCA variants.
Efficacy. The efficacy population consisted of 209 patients with dMMR recurrent or advanced solid tumors whose disease progressed after systemic therapy and who had no satisfactory alternative treatment options. The objective response rate was 41.6% (95% CI, 34.9%–48.6%), with a 9.1% complete response rate and a 32.5% partial response rate. The median follow-up was 27.7 months.[10]
Sources: 10
Identification of biomarker. The VENTANA MMR RxDx Panel is a companion diagnostic device to select patients with dMMR solid tumors for treatment with dostarlimab.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. Pembrolizumab is indicated for adult and pediatric patients with unresectable or metastatic tumor mutational burden–high (TMB-H) solid tumors, whose disease progressed after prior treatment and who have no satisfactory alternative treatment options. TMB-H is defined as ≥10 mutations/megabase (mut/Mb), as determined by a U.S. Food and Drug Administration (FDA)-approved test.
Evidence. FDA approval was based on a retrospective analysis of 10 cohorts of patients with various previously treated unresectable or metastatic TMB-H solid tumors enrolled in KEYNOTE-158 (NCT02628067), a multicenter, nonrandomized, open-label trial. Patients received 200 mg of pembrolizumab intravenously every 3 weeks until unacceptable toxicity or documented disease progression.[1,2][Level of evidence C3]
Sources: KEYNOTE-158 · 1 · 2 · Level of evidence C3
Efficacy. A total of 102 patients (13%) had TMB-H tumors (defined as TMB ≥10 mut/Mb). The objective response rate for these patients was 29% (95% confidence interval, 21%–39%), with a 4% complete response rate and 25% partial response rate.[1] The median follow-up was 13.4 months.[2]
Identification of biomarker. The FoundationOne CDx assay is a companion diagnostic test for pembrolizumab.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. Entrectinib is indicated for adult and pediatric patients with solid tumors and an NTRK gene fusion without a known acquired resistance variant; with disease that is metastatic or where surgical resection is likely to result in severe morbidity; and who have disease progression after treatment or have no satisfactory standard therapy.
Evidence. Five multicenter single-arm clinical trials evaluated the efficacy of entrectinib in patients with NTRK-positive tumors. Three of these trials evaluated a total of 54 adult patients who received entrectinib at various doses and schedules. Two of these trials evaluated a total of 33 pediatric patients.[1,2][Level of evidence C3]
Sources: 1 · 2 · Level of evidence C3
ALKA-372-001; adult patients.
Sources: ALKA-372-001
STARTRK-1 (NCT02097810); adult patients.
Sources: STARTRK-1
STARTRK-2 (NCT02568267); adult patients.
Sources: STARTRK-2
STARTRK-NG (NCT02650401); pediatric patients.
Sources: STARTRK-NG
TAPISTRY (NCT04589845); pediatric patients.
Sources: TAPISTRY
Efficacy. Among the 54 adult patients, the overall response rate, as determined by independent review, was 57% (95% confidence interval [CI], 43%–71%). The median follow-up was 15 months.[1] Among the 33 pediatric patients, the objective response rate was 70% (95% CI, 51%–84%), and the median duration of response was 25.4 months (95% CI, 14.3–not evaluable). The median follow-up was not defined.[2]
Identification of biomarker. Identification of positive NTRK gene fusion status was determined at local laboratories or a central laboratory using nucleic acid-based tests prior to enrollment. Not all NTRK variants are gene fusions. Entrectinib has not shown clinical efficacy in patients with nonfusion NTRK variants..
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. Larotrectinib is indicated for adult and pediatric patients with solid tumors and an NTRK gene fusion without a known acquired resistance variant; with disease that is metastatic or where surgical resection is likely to result in severe morbidity; and who have disease progression after treatment and have no satisfactory alternative treatment options.
Evidence. U.S. Food and Drug Administration (FDA) approval was based on data from three multicenter, open-label, single-arm clinical trials: LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431).[3,4][Level of evidence C3]
Sources: LOXO-TRK-14001 · SCOUT · NAVIGATE · 3 · 4 · Level of evidence C3
Efficacy. Among 55 patients with unresectable or metastatic solid tumors harboring an NTRK gene fusion enrolled across the three trials, the overall response rate was 75% (95% CI, 61%–85%). The complete response rate was 22%, and the partial response rate was 53%. The median follow-up was 8.3 months.[3,5]
Identification of biomarker. NTRK gene fusion status was prospectively determined at local laboratories using next-generation sequencing (NGS) or fluorescence in situ hybridization (FISH). Not all NTRK variants are gene fusions. Entrectinib has not shown clinical efficacy in patients with nonfusion NTRK variants..
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. Repotrectinib is indicated for adult and pediatric patients with an NTRK gene fusion and solid tumors that are locally advanced or metastatic for which surgical resection may cause severe morbidity.
Evidence. FDA approval was based on data from TRIDENT-1 (NCT03093116), a multicenter, single-arm, open-label, multicohort trial.[6-8][Level of evidence C3]
Sources: TRIDENT-1 · 6 · 8 · Level of evidence C3
Efficacy. In 88 adult patients with locally advanced or metastatic NTRK gene fusion–positive solid tumors, the overall response rate was 58% (95% CI, 41%–73%) for patients who had not received prior NTRK tyrosine kinase inhibitors (TKIs) (n = 40) and 50% (95% CI, 35%–65%) for patients who had previously received NTRK TKIs (n = 48). The median duration of response was not estimable in the TKI-naïve group and was 9.9 months (95% CI, 7.4–13.0) in the TKI-pretreated group. The median follow-up was 24.0 months.[6,8]
Identification of biomarker. NTRK gene fusion status was prospectively determined at local laboratories using NGS, Sanger sequencing, reverse transcription–polymerase chain reaction, or FISH. Not all NTRK variants are gene fusions. Repotrectinib has not shown clinical efficacy in patients with nonfusion NTRK variants.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. The combination of dabrafenib and trametinib is indicated for adult and pediatric patients aged 6 years or older with unresectable or metastatic solid tumors and a BRAF V600E variant. Patients must have progressive disease after prior treatment and have no satisfactory alternative treatment options. Dabrafenib in combination with trametinib is not indicated for patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.
Evidence. The U.S. Food and Drug Administration approval was based on data from the following populations:[1-5][Level of evidence C3]
Sources: 1 · 5 · Level of evidence C3
Two open-label multiple cohort trials included 131 adult patients: BRF117019 (NCT02034110) (median follow-up, 47 weeks), and NCI-MATCH (NCT02465060) protocol H (median follow-up, 23.0 months).[1-3]
One trial included 36 pediatric patients: CTMT212X2101 (NCT02124772) (median follow-up, not defined).[4]
Sources: CTMT212X2101 · 4
The approval was also supported by results from COMBI-d (NCT01072175), COMBI-v (NCT01597908), and BRF113928 (NCT01336634).[6]
Efficacy. For the 131 adult patients, the overall response rate was 41% (95% confidence interval [CI], 33%–50%). For the 36 pediatric patients, the overall response rate was 25% (95% CI, 12%–42%).[5]
Sources: 5
Identification of biomarker. Biomarker status was determined at a Clinical Laboratory Improvement Amendments (CLIA) or CLIA-equivalent laboratory.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. Selpercatinib is indicated for adult patients with locally advanced or metastatic solid tumors with a RET gene fusion whose disease meets either of the following criteria: disease progressed during or after prior systemic treatment, or disease with no satisfactory alternative treatment options. This indication is not approved for the pediatric population.
Evidence. Forty-one patients with RET gene fusion–positive tumors (other than non-small cell lung cancer [NSCLC] and thyroid cancer) with disease progression during or after prior systemic treatment or who had no satisfactory alternative treatment options were evaluated in the multicenter, open-label, multicohort LIBRETTO-001 trial (NCT03157128).[1,2][Level of evidence C3]
Sources: LIBRETTO-001 · 1 · 2 · Level of evidence C3
Efficacy. For the 41 evaluable patients with cancers other than NSCLC or thyroid cancer, the objective response rate was 44% (95% confidence interval, 28%–60%). A total of 16 patients had a partial response and 2 patients had a complete response, with a median follow-up of 14.9 months.[1,2]
Identification of biomarker. Clinical Laboratory Improvement Amendments (CLIA) or CLIA-equivalent locally obtained molecular testing was performed at a certified laboratory, with the use of either next-generation sequencing, fluorescence in situ hybridization, or polymerase chain reaction assay.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. Pemigatinib is indicated for adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement. This indication is not approved for the pediatric population.
Evidence. Twenty-eight patients with relapsed or refractory MLNs with FGFR1 rearrangement were evaluated in the multicenter open-label, single-arm FIGHT-203 trial (NCT03011372). Eligible patients were either not candidates for, or had relapsed disease after, allogeneic hematopoietic stem cell transplant or a disease-modifying therapy (e.g., chemotherapy).[1,2][Level of evidence C3]
Sources: FIGHT-203 · 1 · 2 · Level of evidence C3
Efficacy. For all 28 patients (including three patients without evidence of morphologic disease), the complete cytogenetic response rate was 79% (95% confidence interval [CI], 59%–92%). Among the 18 patients with chronic phase disease in the marrow with or without extramedullary disease (EMD), 14 achieved a complete response (78%; 95% CI, 52%–94%). Among the four patients with blast-phase disease in the marrow with or without EMD, two achieved a complete response (duration, 1+ and 94 days). For the three patients with EMD only, one achieved a complete response (duration, 64+ days) with a median follow-up of 25.3 months.[1,2]
Identification of biomarker. Biomarker identification was performed using local cytogenetics and both local and central fluorescence in situ hybridization results.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Indication. T-DXd is indicated for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.[1] This indication is not approved in the pediatric population.
Sources: 1
Evidence. One hundred ninety-two adult patients with previously treated unresectable or metastatic HER2-positive (IHC 3+) solid tumors were enrolled in one of the following three multicenter trials:[2-4][Level of evidence C3]
Sources: 2 · 4 · Level of evidence C3
DESTINY-PanTumor02 (NCT04482309).[2]
Sources: DESTINY-PanTumor02 · 2
DESTINY-Lung01 (NCT03505710).[3]
Sources: DESTINY-Lung01 · 3
DESTINY-CRC02 (NCT04744831).[4]
Sources: DESTINY-CRC02 · 4
Efficacy. The objective response rates were as follows:
51.4% (95% confidence interval [CI], 41.7%–61.0%) for patients in the DESTINY-PanTumor02 trial.
52.9% (95% CI, 27.8%–77.0%) for patients in the DESTINY-Lung01 trial.
46.9% (95% CI, 34.3%–59.8%) for patients in the DESTINY-CRC02 trial.
Identification of biomarker. Eligible patients had centrally confirmed HER2 positivity (IHC 3+).
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Target and mechanism. Atezolizumab blocks the interaction of programmed death-ligand 1 (PD-L1) with programmed cell death 1 (PD-1) and CD80 receptors (B7-1Rs).
Current approvals. Atezolizumab is approved for non-small cell lung cancer,[1-5] small-cell lung cancer,[6] hepatocellular carcinoma,[7] melanoma,[8] and alveolar soft part sarcoma.[9]
Supporting study. Atezolizumab was evaluated in a phase IIa, multibasket, MyPathway study. The preplanned primary end point was objective response rate in patients with TMB-H (≥16 mut/Mb) tumors by FoundationOne TMB testing.[10]
Sources: 10
Study population. This study included 120 patients with advanced solid tumors with TMB ≥10 mut/Mb by any Clinical Laboratory Improvement Amendments (CLIA)-certified assay. Among patients with local or central FoundationOne TMB testing results, 42 had TMB ≥16 mut/Mb tumors, comprising the primary efficacy population, and 49 had TMB ≥10 and <16 mut/Mb tumors, of whom 48 were efficacy evaluable.[10]
Sources: 10
Efficacy. In the primary analysis population of 42 patients with TMB ≥16 mut/Mb tumors, the confirmed objective response rate was 38.1% (95% confidence interval [CI], 23.6%–54.4%) and the disease-control rate (the best response of complete response, partial response, or stable disease >4 months) was 61.9% (95% CI, 45.6%–76.4%), with a median follow-up of 9.9 months.[10][Level of evidence C3]
Sources: 10 · Level of evidence C3
Unspecified Adult Solid Tumor, Protocol Specific
ClinicalTrials.gov recordUnspecified Childhood Solid Tumor, Protocol Specific
ClinicalTrials.gov recordRheumatoid Arthritis
ClinicalTrials.gov recordUnspecified Childhood Solid Tumor, Protocol Specific
ClinicalTrials.gov recordCancer
ClinicalTrials.gov recordHematopoietic Neoplasm
ClinicalTrials.gov recordMelanoma
ClinicalTrials.gov recordCancer, Solid Tumor
ClinicalTrials.gov recordMSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers
ClinicalTrials.gov recordSolid Tumours
ClinicalTrials.gov recordCancer
ClinicalTrials.gov recordSolid Tumor
ClinicalTrials.gov recordMetastatic Urothelial Cancer and Other Malignant Solid Tumors
ClinicalTrials.gov recordSolid Tumors Harboring NTRK Fusion
ClinicalTrials.gov recordCancer
ClinicalTrials.gov recordRefractory or Recurrent Solid Tumors, Excluding CNS Tumors
ClinicalTrials.gov recordPediatrics, Solid Tumors
ClinicalTrials.gov recordColorectal Carcinoma
ClinicalTrials.gov recordAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma,...
ClinicalTrials.gov recordSolid Tumor
ClinicalTrials.gov recordPediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies
ClinicalTrials.gov recordAdvanced Solid Tumors
ClinicalTrials.gov recordSolid Tumors Harboring NTRK Fusion
ClinicalTrials.gov recordSolid Tumors Harboring NTRK Fusion
ClinicalTrials.gov recordSolid Tumors
ClinicalTrials.gov recordSolid Tumors, CNS Tumors
ClinicalTrials.gov recordNeoplasms
ClinicalTrials.gov recordAdvanced Cancer
ClinicalTrials.gov recordMPN (Myeloproliferative Neoplasms)
ClinicalTrials.gov recordAdvanced Cancer
ClinicalTrials.gov recordPediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
ClinicalTrials.gov recordSolid Tumor
ClinicalTrials.gov recordAdvanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
ClinicalTrials.gov recordRelapsed Solid Tumor, Refractory Solid Tumor
ClinicalTrials.gov recordAdvanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
ClinicalTrials.gov recordRelapsed or Refractory Solid Tumors
ClinicalTrials.gov recordPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2...
ClinicalTrials.gov recordFGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation, FGFR2 Gene Activation, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma,...
ClinicalTrials.gov recordSolid Tumors
ClinicalTrials.gov recordAdvanced Colorectal Cancer
ClinicalTrials.gov recordLow-grade Glioma, Advanced Solid Tumor
ClinicalTrials.gov recordLocally Advanced Solid Tumor, Metastatic Solid Tumor
ClinicalTrials.gov recordNeuroblastoma
ClinicalTrials.gov recordRhabdoid Neoplasm of CNS
ClinicalTrials.gov recordGood Prognosis Metastatic Gestational Trophoblastic Tumor, Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor, Uterine Corpus Choriocarcinoma
ClinicalTrials.gov recordAdult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Steroid Cell Tumor
ClinicalTrials.gov recordLeiomyosarcoma, Uterine Neoplasm
ClinicalTrials.gov recordLeiomyosarcoma, Uterine Neoplasm
ClinicalTrials.gov recordRheumatoid Arthritis, Crohn's Disease
ClinicalTrials.gov recordLymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
ClinicalTrials.gov recordLymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
ClinicalTrials.gov recordMalignant Pleural Mesothelioma, Solid Tumors
ClinicalTrials.gov recordMalignant Ovarian Epithelial Tumor, Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules,...
ClinicalTrials.gov recordCancer, Spinal Disease, Vertebral Compression Fractures
ClinicalTrials.gov recordSolid Tumors, Cancer
ClinicalTrials.gov recordOvarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian...
ClinicalTrials.gov recordAdvanced Solid Tumors
ClinicalTrials.gov recordSolid Tumors
ClinicalTrials.gov recordAdvanced Solid Tumors, Advanced Recurrent Ovarian Tumors
ClinicalTrials.gov recordChoriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor, FIGO Stage II Gestational Trophoblastic Tumor, FIGO Stage III Gestational Trophoblastic Tumor, Hydatidiform Mole
ClinicalTrials.gov recordSolid Tumor and Hematologic Malignancies
ClinicalTrials.gov recordMalignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid...
ClinicalTrials.gov recordSolid Tumors and Hematologic Malignancy
ClinicalTrials.gov recordAdvanced Solid Tumors
ClinicalTrials.gov recordAdvanced Cancer
ClinicalTrials.gov recordSolid Tumors
ClinicalTrials.gov recordHematologic Malignancies, Solid Tumor
ClinicalTrials.gov recordGestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor
ClinicalTrials.gov recordSolid Tumors
ClinicalTrials.gov recordHematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
ClinicalTrials.gov recordBrain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Recurrent Visual Pathway...
ClinicalTrials.gov recordSolid Tumor
ClinicalTrials.gov recordPrimary Malignant Liver Neoplasm
ClinicalTrials.gov recordAdvanced Solid Tumor
ClinicalTrials.gov recordRecurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory...
ClinicalTrials.gov recordSolid Tumors
ClinicalTrials.gov recordLocally Advanced or Metastatic Solid Tumor
ClinicalTrials.gov recordLocally Advanced or Metastatic Solid Tumor
ClinicalTrials.gov recordSolid Tumors
ClinicalTrials.gov recordSolid Tumor
ClinicalTrials.gov recordMalignant Liver Neoplasm
ClinicalTrials.gov recordAdvanced Cancer
ClinicalTrials.gov recordSolid Tumor
ClinicalTrials.gov recordSolid Tumor
ClinicalTrials.gov recordSolid Tumor, Adult
ClinicalTrials.gov recordParotid Neoplasm, Thyroid Neoplasms, Head and Neck Neoplasms, Surgery, Nerve Injury, Imaging
ClinicalTrials.gov recordAdvanced/Metastatic Solid Tumor
ClinicalTrials.gov recordAdvanced Solid Tumors
ClinicalTrials.gov recordAdvanced Solid Tumors
ClinicalTrials.gov recordAdvanced Solid Tumors
ClinicalTrials.gov recordAdenoma
Adrenal Cortical Adenoma
Adult Leiomyosarcoma
Adult Liposarcoma
Adult Malignant Peripheral Nerve Sheath Tumor
Adult Pineocytoma
Adult Teratoma
Angiomatoid Fibrous Histiocytoma
Atypical Fibroxanthoma
B-Cell Neoplasm
Brenner Tumor
Carcinoma In Situ
Carcinosarcoma
Childhood Anaplastic Oligodendroglioma
Chondrosarcoma
Choriocarcinoma
Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy.
Clear Cell Adenocarcinoma
Condyloma Acuminatum
Dermatofibrosarcoma Protuberans
Desmoid Fibromatosis
Endocrine Carcinoma
Endometrioid Adenocarcinoma
Fibrohistiocytic Neoplasm
FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Gastroesophageal Junction Carcinoma
Gestational Trophoblastic Tumor
Head and Neck Neoplasm
Histiocytoma
Human Papillomavirus-Related Carcinoma
1.3 Biliary Tract Cancers IMFINZI, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).
Intermediate Grade Lung Neuroendocrine Neoplasm
Intestinal Neoplasm
Juvenile Xanthogranuloma
1.12 Biliary Tract Cancer KEYTRUDA QLEX, in combination with gemcitabine and cisplatin, is indicated for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
1.14 Biliary Tract Cancer KEYTRUDA, in combination with gemcitabine and cisplatin, is indicated for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
Kidney Carcinoma
Kidney Neoplasm
Leiomyosarcoma
Light Chain Deposition Disease
Liposarcoma
Liquid Tumor
Liver Neoplasm
Low Grade Lung Neuroendocrine Neoplasm
Lung Neoplasm
Malignant Abdominal Neoplasm
Malignant Adult Hemangiopericytoma
Malignant Ampulla of Vater Neoplasm
Malignant Biliary Tract Neoplasm
Malignant Bone Neoplasm
Malignant Endocrine Neoplasm
Malignant Head and Neck Neoplasm
Malignant Kidney Neoplasm
Malignant Lung Neoplasm
Malignant Pelvic Neoplasm
Malignant Peripheral Nerve Sheath Tumor
Malignant Peritoneal Neoplasm
Malignant Prostate Neoplasm
Malignant Ureter Neoplasm
Malignant Uterine Corpus Neoplasm
Malignant Uterine Neoplasm
Mesenchymal Chondrosarcoma
Micropapillary Serous Carcinoma
Mixed Mesodermal (Mullerian) Tumor
Monoclonal Gammopathy of Undetermined Significance
Mucinous Adenocarcinoma
Myeloid Neoplasm
Myoma
Nerve Sheath Neoplasm
Neuroendocrine Neoplasm
Oligoastrocytoma
Ovarian Neoplasm
Pancreatic Intraductal Papillary Mucinous Neoplasm
Papillary Adenocarcinoma
Papilloma
PEComa
Pericytic Neoplasm
Peritoneal Neoplasm
Pleomorphic Xanthoastrocytoma
Poor Prognosis Metastatic Gestational Trophoblastic Tumor
Primitive Neuroectodermal Tumor
Recurrent Childhood Anaplastic Oligoastrocytoma
Recurrent Childhood Anaplastic Oligodendroglioma
Recurrent Childhood Gliomatosis Cerebri
Recurrent Childhood Oligoastrocytoma
Recurrent Childhood Oligodendroglioma
Recurrent Histiocytic and Dendritic Cell Neoplasm
Recurrent Rhabdoid Tumor
Refractory Histiocytic and Dendritic Cell Neoplasm
Refractory Peripheral Primitive Neuroectodermal Tumor
Refractory Rhabdoid Tumor
Rhabdoid Tumor
Squamous Cell Neoplasm
Teratoma
Thoracic Neoplasm
Transplant-Related Carcinoma
Ureter Carcinoma
Ureter Neoplasm
Urethra Neoplasm
Uterine Carcinosarcoma
Uterine Neoplasm
VALSTAR is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable...
Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test
ABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelABRILADA is a tumor necrosis factor (TNF) blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelAdalimumab-fkjp is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving...
DailyMed labelAdalimumab-aaty is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...
DailyMed labelAdalimumab-adaz is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...
DailyMed labelAdalimumab-aacf is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving...
DailyMed labelAdalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...
DailyMed labelAdalimumab-adbm is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...
DailyMed labelAdalimumab-bwwd is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...
DailyMed labelAdalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...
DailyMed labelAdalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...
DailyMed labelAdalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients...
DailyMed label1 INDICATIONS & USAGE Allopurinol tablet is indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management...
DailyMed label1 INDICATIONS & USAGE Allopurinol tablet is indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management...
DailyMed labelAllopurinol Tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and...
DailyMed labelALOPRIM is indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot...
DailyMed labelAMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelAMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelAMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelAVSOLA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an...
DailyMed labelINDICATIONS & USAGE Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or...
DailyMed labelCIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate...
DailyMed labelCRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for: The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. ( 1.1 ) The treatment of FGF23-related...
DailyMed labelCYLTEZO is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed label1. INDICATIONS AND USAGE DECNUPAZ is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). DECNUPAZ is a CD123-directed antibody and alkylating agent conjugate indicated for the...
DailyMed labelElitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and...
DailyMed labelELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic...
DailyMed labelEnbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 )...
DailyMed labelFYARRO ® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is an mTOR inhibitor indicated for the treatment of adult patients...
DailyMed labelHADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...
DailyMed labelHADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelHADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...
DailyMed labelHULIO is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...
DailyMed labelHUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelHUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelHUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ) : reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...
DailyMed labelHYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelHYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelIDACIO is a tumor necrosis factor (TNF) blocker indicated for: • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...
DailyMed labelIDACIO is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...
DailyMed labelILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold...
DailyMed labelINFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who...
DailyMed labelInfliximab is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had...
DailyMed labelKINERET is an interleukin-1 receptor antagonist indicated for: Rheumatoid Arthritis (RA) Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients...
DailyMed labelOLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of...
DailyMed labelPEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. Limitations of Use The safety and efficacy of PEDMARK have not...
DailyMed labelREMICADE is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an...
DailyMed labelRENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an...
DailyMed labelSIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelSIMLANDI is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA): Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function...
DailyMed labelSIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 ) adult patients with active psoriatic...
DailyMed labelSIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA)...
DailyMed labelINDICATIONS AND USAGE TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral...
DailyMed labelVITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, are metastatic or where...
DailyMed labelVITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: • have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, • are metastatic or where...
DailyMed labelYUFLYMA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelYUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with...
DailyMed labelYUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical...
DailyMed labelZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 )...
DailyMed label